Real World Treatment Practices for Chronic Lymphocytic Leukemia in Japan: An Observational Database Research Study...

Area of Science:

• Hematology
• Oncology
• Real-world evidence studies

Background:

• Limited real-world data exists on chronic lymphocytic leukemia (CLL) treatment practices in Japan.
• Understanding current treatment patterns and healthcare resource utilization is crucial for improving patient outcomes.

Purpose of the Study:

• To analyze real-world treatment practices and healthcare resource utilization for chronic lymphocytic leukemia (CLL) in Japan.
• To establish a benchmark for future studies on CLL management in the Japanese healthcare setting.

Main Methods:

• Retrospective analysis of the Japanese Medical Data Vision database (CLIMBER-DBR study).
• Inclusion of 2562 patients with newly diagnosed CLL (CLL-1 cohort) and 930 patients receiving treatment (CLL-2 cohort) between March 2013 and February 2018.
• Assessment of treatment regimens, time to treatment initiation, and time to subsequent lines of therapy.

Main Results:

• Median follow-up of 721 days in the CLL-1 cohort; median time to first-line treatment was 1331 days.
• Most frequent first-line regimens included fludarabine alone (17.7%), cyclophosphamide alone (13.7%), and bendamustine/rituximab (8.2%).
• Median times to second-line and third-line treatments were 1066 and 1795 days, respectively.

Conclusions:

• The CLIMBER-DBR study is the first database research to assess current CLL treatment practices in Japan.
• Treatment patterns observed were significantly influenced by drug approval and reimbursement status during the study period.
• This study provides a vital benchmark for future research and clinical practice concerning CLL in Japan.